Navigation Links
Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Date:3/25/2009

CALGARY, March 25 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) today announced the completion of patient enrolment in its U.K. clinical trial to evaluate the anti-tumour effects of intravenous administration of REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients with advanced cancers including breast, and head and neck. The principal investigators are Dr. Johann de Bono of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, U.K., and Professor Jeff Evans of the University of Glasgow, Scotland.

A total of 15 patients were enrolled in the trial. Of the ten patients evaluable for response, two patients (breast and nasopharyngeal) had partial responses (PRs) and five patients had SD (stable disease) for 4-8 cycles, for a total disease control rate (CR (Complete response)+PR +SD) of 70%.

"The results to date using this treatment combination in late-stage cancer patients indicate that further studies using this drug combination are warranted," said Dr. Brad Thompson, President and CEO of Oncolytics. "We plan to initiate further studies in the U.S. using a modified dosage regime of REOLYSIN and the commonly used U.S. dosage of gemcitabine (800 mg/m(2)) in patients with advanced or metastatic pancreatic cancer in partnership with the Cancer Therapy & Research Center at The University of Texas Health Science Center in San Antonio, (CTRC at UTHSCSA)."

The U.K. trial (REO 009) is an open-label, dose-escalating, non-randomized study of REOLYSIN given intravenously with gemcitabine every three weeks. Gemcitabine (1000 mg/m(2)) was administered to patients in combination with escalating dosages of REOLYSIN intravenously.

Eligible patients included those who had been diagnosed with advanced or metastatic solid tumours including pancreatic, l
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
3. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
4. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
5. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
7. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
8. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
9. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2014)... , Nov. 17, 2014 Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today the formation of a Medical ... to the Company as it advances the Phase ... the treatment of cutaneous T-cell lymphoma (CTCL), a ...
(Date:11/15/2014)... MA (PRWEB) November 13, 2014 Collaborative ... announced they were named one of the Boston Globe’s ... the Medium Sized Businesses in Massachusetts to receive the ... honors employers who take care of their most valuable ... awards are presented annually, and are based on an ...
(Date:11/15/2014)... The International Society for Cardiovascular ... society’s Governing Board has grown with the additions ... officer and Dr. Charles Simonton, divisional vice president, ... Mr. Rowe and Dr. Simonton are both medical ... , Dr. Nabil Dib, ISCTR President stated, “We ...
(Date:11/15/2014)... November 14, 2014 The "Operating ... Surgical, Performance), by Application (Perioperative, Preoperative, operating room ... (Web-Based, On-Premise) - Global Forecast to 2019.” defines ... an analysis and forecast of value by product, ... Along with this, the value and volumes of ...
Breaking Biology Technology:Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 2Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 3Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 4Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 5Soligenix Announces Formation of Cutaneous T-Cell Lymphoma Medical Advisory Board 6Collaborative Consulting Honored with Boston Globe Top Places to Work 2014 2International Society for Cardiovascular Translational Research Governing Board Adds Medical Industry Leaders 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 3Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 4
... WA, March 10 /PRNewswire-FirstCall/ - Oncothyreon Inc.,(Nasdaq: ONTY ... the year and quarter ended December 31, 2007. All ... Net loss for the year ended December 31, ... share, compared with $36.4 million, or $2.38,per basic and ...
... (Nasdaq: MNKD ) today issued the following ... is absolutely committed to the continued development of ... small,patient-friendly Medtone(R) inhaler to deliver Technosphere(R) Insulin to,patients ... closely matches the pattern,of insulin secretion seen in ...
... - Dr. Brad Thompson, President,and CEO of Oncolytics ... a,corporate overview of the Company at the BioSquare ... is being held at the Congress Center in,Basel, ... Biotech Inc., Oncolytics is a Calgary-based biotechnology ...
Cached Biology Technology:Oncothyreon reports full year and fourth quarter 2007 financial results 2Oncothyreon reports full year and fourth quarter 2007 financial results 3Oncothyreon reports full year and fourth quarter 2007 financial results 4Oncothyreon reports full year and fourth quarter 2007 financial results 5Oncothyreon reports full year and fourth quarter 2007 financial results 6Oncothyreon reports full year and fourth quarter 2007 financial results 7MannKind Corporation Response to Recent Market Events 2MannKind Corporation Response to Recent Market Events 3MannKind Corporation Response to Recent Market Events 4MannKind Corporation Response to Recent Market Events 5MannKind Corporation Response to Recent Market Events 6Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008 2
(Date:11/4/2014)... November 4, 2014   ... growth   Fuel3D , a developer of ... funding round totaling $6.4 million (£4 million). This funding builds ... earlier this year and paves the way for the commercial ... The funding round was led by Chimera Partners and ...
(Date:11/4/2014)... Lithuania , Nov. 4, 2014   ... technologies, today announced that the latest version of ... in the Ongoing MINEX evaluation organized ... of fingerprint algorithms using the INCITS 378 fingerprint ... mandatory requirement in public tenders in ...
(Date:11/3/2014)... University of Colorado Cancer Center study published ... of Sciences describes the activity of a recently ... 37 or IL-37. It has been known to limit ... the adaptive immune system: IL-37 inhibits the ability of ... , "Knowing this mechanism that underlies IL-37,s effect on ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... Vegas, NVCONRAD, a leading reproductive health research organization, will announce ... at the Reproductive Health 2011 Conference in Las Vegas, Nevada. ... implemented at six clinical sites in the U.S. showed that ... similar to traditional diaphragms. In addition, SILCS was ...
... -- Decreasing expression of a protein associated with susceptibility ... while improving their hormonal response to stress, a study ... found. The lack of this protein, FKBP51, did not ... The study suggests that drug discovery efforts aimed ...
... MD The Federation of American Societies for Experimental ... client, the Histochemical Society (HCS). The executive leadership ... include general management support, membership marketing, recruitment, and retention, ... Executive Director of HCS, William Stahl, PhD commented, "HCS ...
Cached Biology News:CONRAD presents results of pivotal contraceptive study at Reproductive Health 2011 2CONRAD presents results of pivotal contraceptive study at Reproductive Health 2011 3Lack of protein FKBP51 in old mice improves resilience to depressive behavior 2
...
... Anti-HMGN2/HMG-17 Immunogen : ... Tris-glycine, pH7.4, 5mg/ml BSA, 0.15M ... the addition of glycerol to ... by immunoblot on acid extracts ...
...
... different human fetal normal tissues are ... upon request. Customers can choose ... set, and pay 70% of the ... P Set products are for research ...
Biology Products: